GSK completes study for COPD treatment
Pharmaceuticals giant GlaxoSmithKline announced on Friday afternoon that it has completed, along with partner Theravance, the phase III programme of a 52-week safety study for its UMEC/VI medicine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Pharmaceuticals giant GlaxoSmithKline announced on Friday afternoon that it has completed, along with partner Theravance, the phase III programme of a 52-week safety study for its UMEC/VI medicine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
The 6,000-patient study, along with other recently completed studies, "supports GSK's plans to commence global regulatory submissions for UMEC/VI from the end of 2012," the firm said.
UMEC/VI is one of several late-stage assets in Glaxo's respiratory development portfolio which have not yet been approved anywhere in the world.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Shares were trading 0.69% higher at 1,461p before the close.
BC
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Average earnings by region – how does your income compare?
There are significant regional differences when it comes to how much the average worker earns. We explore the data and reveal where in the UK average earnings are highest.
-
St James’s Place confirms new fees – what it means for customers
The UK’s largest wealth manager is replacing its “opaque” and “complex” pricing structure. We explain the new charges, and when they will kick in